{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T04:54:07Z","timestamp":1789620847321,"version":"build-2803163510"},"reference-count":127,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2017,4,1]],"date-time":"2017-04-01T00:00:00Z","timestamp":1491004800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2017,2,24]],"date-time":"2017-02-24T00:00:00Z","timestamp":1487894400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"name":"Amgen (Europe)"}],"content-domain":{"domain":["clinicalkey.jp","clinicalkey.com","croh-online.com","clinicalkey.es","clinicalkey.com.au","clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Critical Reviews in Oncology\/Hematology"],"published-print":{"date-parts":[[2017,4]]},"DOI":"10.1016\/j.critrevonc.2017.02.007","type":"journal-article","created":{"date-parts":[[2017,2,14]],"date-time":"2017-02-14T13:45:25Z","timestamp":1487079925000},"page":"153-170","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":41,"special_numbering":"C","title":["How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients?"],"prefix":"10.1016","volume":"112","author":[{"given":"Pieter","family":"Sonneveld","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Edwin","family":"De Wit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Philippe","family":"Moreau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.critrevonc.2017.02.007_bib0005","series-title":"Kyprolis (Carfilzomib) Summary of Product Characteristics","author":"Amgen","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0010","doi-asserted-by":"crossref","first-page":"492","DOI":"10.1182\/blood.V98.2.492","article-title":"Extended survival in advanced and refractory multiple myeloma after single-agent thalidomide: identification of prognostic factors in a phase 2 study of 169 patients","volume":"98","author":"Barlogie","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0015","doi-asserted-by":"crossref","first-page":"1766","DOI":"10.1093\/annonc\/mdl313","article-title":"Lenalidomide and pegylated liposomal doxorubicin-based chemotherapy for relapsed or refractory multiple myeloma: safety and efficacy","volume":"17","author":"Baz","year":"2006","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0020","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1182\/blood-2015-11-682518","article-title":"Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma","volume":"127","author":"Baz","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0025","doi-asserted-by":"crossref","first-page":"670","DOI":"10.3324\/haematol.2014.119735","article-title":"Phase I\/II study of the combination of panobinostat and carfilzomib in patients with relapsed\/refractory multiple myeloma","volume":"100","author":"Berdeja","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0030","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.8513","article-title":"A phase I\/II study of the combination of panobinostat (PAN) and carfilzomib (CFZ) in patients (pts) with relapsed or relapsed\/refractory multiple myeloma (MM)","volume":"33","author":"Berdeja","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0035","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1111\/j.1365-2141.2011.08573.x","article-title":"Guidelines for the diagnosis and management of multiple myeloma 2011","volume":"154","author":"Bird","year":"2011","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0040","series-title":"Guidelines for the Diagnosis and Management of Multiple Myeloma","author":"Bird","year":"2014"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0045","series-title":"Guidelines for the Diagnosis and Management of Multiple Myeloma","author":"Bird","year":"2014"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0050","doi-asserted-by":"crossref","first-page":"1532","DOI":"10.1182\/blood-2014-10-551531","article-title":"How I treat relapsed myeloma","volume":"125","author":"Blade","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0055","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1016\/j.jpainsymman.2012.11.003","article-title":"Living with advanced but stable multiple myeloma: a study of the symptom burden and cumulative effects of disease and intensive (hematopoietic stem cell transplant-based) treatment on health-related quality of life","volume":"46","author":"Boland","year":"2013","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0060","doi-asserted-by":"crossref","first-page":"4745","DOI":"10.1182\/blood-2010-07-294983","article-title":"Efficacy and safety of once-weekly bortezomib in multiple myeloma patients","volume":"116","author":"Bringhen","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0065","series-title":"Empliciti (elotuzumab) Summary of Product Characteristics","author":"Bristol-Myers Squibb","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0070","series-title":"Celgene Corporation Thalomid\u00ae Highlights of Prescribing Information","author":"Celgene Corporation Thalomid","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0075","series-title":"Thalidomide Celgene Summary of Product Characteristics","author":"Celgene Europe Ltd","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0080","series-title":"Revlimid (lenalidomide) Summary of Product Characteristics","author":"Celgene Europe Ltd","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0085","series-title":"Imnovid (Pomalidomide) Summary of Product Characteristics","author":"Celgene Europe Ltd","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0090","doi-asserted-by":"crossref","first-page":"3327","DOI":"10.1002\/cncr.30174","article-title":"A phase 1 dose-escalation study of filanesib plus bortezomib and dexamethasone in patients with recurrent\/refractory multiple myeloma","volume":"122","author":"Chari","year":"2016","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0095","first-page":"1942","article-title":"Anti tumor activity of selinexor (KPT-330), a first-in-class oral selective inhibitor of nuclear export (SINE) XPO1\/CRM1 antagonist in patients (pts) with relapsed\/refractory multiple myeloma (MM) or Waldenstrom\u2019s macroglobulinemia (WM)","volume":"122","author":"Chen","year":"2013","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0100","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1038\/leu.2013.247","article-title":"IMWG consensus on risk stratification in multiple myeloma","volume":"28","author":"Chng","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0105","doi-asserted-by":"crossref","first-page":"486","DOI":"10.1111\/j.0902-4441.2006.t01-1-EJH2783.x","article-title":"Long-term results of thalidomide in refractory and relapsed multiple myeloma with emphasis on response duration","volume":"77","author":"Cibeira","year":"2006","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0110","doi-asserted-by":"crossref","first-page":"632","DOI":"10.3109\/10428194.2011.622422","article-title":"Efficacy of bendamustine in relapsed\/refractory myeloma patients: results from the French compassionate use program","volume":"53","author":"Damaj","year":"2012","journal-title":"Leuk. Lymphoma"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0115","doi-asserted-by":"crossref","first-page":"979","DOI":"10.1007\/s40265-016-0596-x","article-title":"Venetoclax: first global approval","volume":"76","author":"Deeks","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0120","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1016\/S1470-2045(10)70068-1","article-title":"Treatment-related peripheral neuropathy in multiple myeloma: the challenge continues","volume":"11","author":"Delforge","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0125","doi-asserted-by":"crossref","first-page":"991","DOI":"10.1023\/A:1011132808904","article-title":"Thalidomide and dexamethasone combination for refractory multiple myeloma","volume":"12","author":"Dimopoulos","year":"2001","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0130","doi-asserted-by":"crossref","first-page":"112","DOI":"10.1038\/sj.thj.6200326","article-title":"Pulsed cyclophosphamide, thalidomide and dexamethasone: an oral regimen for previously treated patients with multiple myeloma","volume":"5","author":"Dimopoulos","year":"2004","journal-title":"Hematol. J."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0135","doi-asserted-by":"crossref","first-page":"2123","DOI":"10.1056\/NEJMoa070594","article-title":"Lenalidomide plus dexamethasone for relapsed or refractory multiple myeloma","volume":"357","author":"Dimopoulos","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0140","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/S1470-2045(13)70398-X","article-title":"Vorinostat or placebo in combination with bortezomib in patients with multiple myeloma (VANTAGE 088): a multicentre, randomised, double-blind study","volume":"14","author":"Dimopoulos","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0145","doi-asserted-by":"crossref","first-page":"1573","DOI":"10.1038\/leu.2014.60","article-title":"Expert panel consensus statement on the optimal use of pomalidomide in relapsed and refractory multiple myeloma","volume":"28","author":"Dimopoulos","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0150","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","article-title":"Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study","volume":"17","author":"Dimopoulos","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0155","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","article-title":"Daratumumab, lenalidomide, and dexamethasone for multiple myeloma","volume":"375","author":"Dimopoulos","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0160","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1016\/j.beha.2005.01.024","article-title":"Neurological aspects of multiple myeloma and related disorders","volume":"18","author":"Dispenzieri","year":"2005","journal-title":"Best Pract. Res. Clin. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0165","series-title":"Velcade Scientific Discussion","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0170","series-title":"Velcade Assessment Report","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0175","series-title":"Velcade Summary of Opinion (Post-authorisation)","author":"European Medicines Agency","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0180","doi-asserted-by":"crossref","first-page":"856","DOI":"10.1038\/sj.leu.2403322","article-title":"The oral combination of thalidomide, cyclophosphamide and dexamethasone (ThaCyDex) is effective in relapsed\/refractory multiple myeloma","volume":"18","author":"Garcia-Sanz","year":"2004","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0185","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1200\/JCO.2011.37.4918","volume":"30","author":"Garderet","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0190","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1111\/j.1365-2141.2011.08887.x","article-title":"Bendamustine, thalidomide and dexamethasone is an effective salvage regimen for advanced stage multiple myeloma","volume":"156","author":"Grey-Davies","year":"2012","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0195","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1586\/17474086.2015.1001360","article-title":"Multiple myeloma: is a shift toward continuous therapy needed to move forward?","volume":"8","author":"Guglielmelli","year":"2015","journal-title":"Expert Rev. Hematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0200","article-title":"A randomized phase III study of carfilzomib vs low-dose corticosteroids with optional cyclophosphamide in relapsed and refractory multiple myeloma (FOCUS)","author":"H\u00e1jek","year":"2016","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0205","doi-asserted-by":"crossref","first-page":"3453","DOI":"10.1182\/blood.V124.21.3453.3453","article-title":"Oprozomib and dexamethasone in patients with relapsed and\/or refractory multiple myeloma: initial results from the dose escalation portion of a phase 1b\/2, multicenter, open-label study","volume":"124","author":"Hari","year":"2014","journal-title":"Blood"},{"issue":"Suppl. 5","key":"10.1016\/j.critrevonc.2017.02.007_bib0210","doi-asserted-by":"crossref","first-page":"v155","DOI":"10.1093\/annonc\/mdq178","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"21","author":"Harousseau","year":"2010","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0215","doi-asserted-by":"crossref","first-page":"6274","DOI":"10.1182\/blood-2011-03-339879","article-title":"A high rate of durable responses with romidepsin, bortezomib, and dexamethasone in relapsed or refractory multiple myeloma","volume":"118","author":"Harrison","year":"2011","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0220","doi-asserted-by":"crossref","first-page":"e269","DOI":"10.1016\/j.clml.2015.07.563","article-title":"Phase 1 clinical trial of marizomib (MRZ, NPI-0052) in patients with advanced malignancies including multiple myeloma: study NPI-0052-102 (NCT00629473) final results","volume":"15","author":"Harrison","year":"2015","journal-title":"Clin. Lymph Myel. Leuk."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0225","doi-asserted-by":"crossref","first-page":"E86","DOI":"10.1002\/ajh.23967","article-title":"The addition of dexamethasone to bortezomib for patients with relapsed multiple myeloma improves outcome but ongoing maintenance therapy has minimal benefit","volume":"90","author":"Harrison","year":"2015","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0230","doi-asserted-by":"crossref","first-page":"3046","DOI":"10.1182\/blood.V116.21.3046.3046","article-title":"Optimal treatment sequencing in multiple myeloma: an exploratory modeling approach","volume":"116","author":"Heeg","year":"2010","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0235","doi-asserted-by":"crossref","first-page":"889","DOI":"10.4065\/81.7.889","article-title":"Phase 2 study of pegylated liposomal doxorubicin, vincristine, decreased-frequency dexamethasone, and thalidomide in newly diagnosed and relapsed-refractory multiple myeloma","volume":"81","author":"Hussein","year":"2006","journal-title":"Mayo Clin. Proc."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0240","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1111\/j.1365-2141.2004.05188.x","article-title":"A phase 2 study of two doses of bortezomib in relapsed or refractory myeloma","volume":"127","author":"Jagannath","year":"2004","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0245","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1111\/j.1365-2141.2008.07359.x","article-title":"Updated survival analyses after prolonged follow-up of the phase 2, multicenter CREST study of bortezomib in relapsed or refractory multiple myeloma","volume":"143","author":"Jagannath","year":"2008","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0250","doi-asserted-by":"crossref","first-page":"1801","DOI":"10.1182\/blood-2012-04-422683","article-title":"A phase 1\/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma","volume":"120","author":"Jakubowiak","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0255","doi-asserted-by":"crossref","first-page":"1960","DOI":"10.1200\/JCO.2011.37.7069","article-title":"Phase I trial of anti-CS1 monoclonal antibody elotuzumab in combination with bortezomib in the treatment of relapsed\/refractory multiple myeloma","volume":"30","author":"Jakubowiak","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0260","doi-asserted-by":"crossref","first-page":"2833","DOI":"10.1182\/blood-2016-01-694604","article-title":"Randomized phase 2 study: elotuzumab plus bortezomib\/dexamethasone vs bortezomib\/dexamethasone for relapsed\/refractory MM","volume":"127","author":"Jakubowiak","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0265","series-title":"Velcade\u00ae (Bortezomib) Summary of Product Characteristics","author":"Janssen-Cilag","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0270","series-title":"Darzalex (Daratumumab) Summary of Product Characteristics","author":"Janssen-Cilag","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0275","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1007\/s00520-013-1991-4","article-title":"Effect of general symptom level, specific adverse events, treatment patterns, and patient characteristics on health-related quality of life in patients with multiple myeloma: results of a European, multicenter cohort study","volume":"22","author":"Jordan","year":"2014","journal-title":"Support. Care Cancer"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0280","doi-asserted-by":"crossref","first-page":"89","DOI":"10.1046\/j.1365-2141.2000.01983.x","article-title":"Frequent good partial remissions from thalidomide including best response ever in patients with advanced refractory and relapsed myeloma","volume":"109","author":"Juliusson","year":"2000","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0285","doi-asserted-by":"crossref","first-page":"4137","DOI":"10.1182\/blood-2008-10-184135","article-title":"Lenalidomide, adriamycin, and dexamethasone (RAD) in patients with relapsed and refractory multiple myeloma: a report from the German Myeloma Study Group DSMM (Deutsche Studiengruppe Multiples Myelom)","volume":"113","author":"Knop","year":"2009","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0290","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1046\/j.1365-2141.2003.04473.x","article-title":"Hyperfractionated cyclophosphamide in combination with pulsed dexamethasone and thalidomide (HyperCDT) in primary refractory or relapsed multiple myeloma","volume":"122","author":"Kropff","year":"2003","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0295","doi-asserted-by":"crossref","first-page":"784","DOI":"10.3324\/haematol.2011.044271","article-title":"Thalidomide versus dexamethasone for the treatment of relapsed and\/or refractory multiple myeloma: results from OPTIMUM, a randomized trial","volume":"97","author":"Kropff","year":"2012","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0300","doi-asserted-by":"crossref","first-page":"1047","DOI":"10.1182\/blood-2014-01-548941","article-title":"Phase 1 study of weekly dosing with the investigational oral proteasome inhibitor ixazomib in relapsed\/refractory multiple myeloma","volume":"124","author":"Kumar","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0305","doi-asserted-by":"crossref","first-page":"1122","DOI":"10.1038\/leu.2013.313","article-title":"Continued improvement in survival in multiple myeloma: changes in early mortality and outcomes in older patients","volume":"28","author":"Kumar","year":"2014","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0310","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1182\/blood-2014-05-573741","article-title":"Dinaciclib, a novel CDK inhibitor, demonstrates encouraging single-agent activity in patients with relapsed multiple myeloma","volume":"125","author":"Kumar","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0315","doi-asserted-by":"crossref","first-page":"5008","DOI":"10.1200\/JCO.2009.23.6802","article-title":"Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma","volume":"27","author":"Lacy","year":"2009","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0320","doi-asserted-by":"crossref","first-page":"643","DOI":"10.1007\/s00277-014-2238-2","article-title":"Bendamustine in combination with thalidomide and dexamethasone is a viable salvage option in myeloma relapsed and\/or refractory to bortezomib and lenalidomide","volume":"94","author":"Lau","year":"2015","journal-title":"Ann. Hematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0325","doi-asserted-by":"crossref","first-page":"349","DOI":"10.1002\/ajh.23639","article-title":"Mature results of MM-011: a phase I\/II trial of liposomal doxorubicin, vincristine, dexamethasone, and lenalidomide combination therapy followed by lenalidomide maintenance for relapsed\/refractory multiple myeloma","volume":"89","author":"Lazaryan","year":"2014","journal-title":"Am. J. Hematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0330","doi-asserted-by":"crossref","first-page":"1264","DOI":"10.1158\/1078-0432.CCR-10-1805","article-title":"Treatment options for relapsed and refractory multiple myeloma","volume":"17","author":"Lonial","year":"2011","journal-title":"Clin. Cancer Res."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0335","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","article-title":"Elotuzumab therapy for relapsed or refractory multiple myeloma","volume":"373","author":"Lonial","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0340","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0345","doi-asserted-by":"crossref","first-page":"985","DOI":"10.1182\/blood-2013-08-521468","article-title":"Bendamustine-bortezomib-dexamethasone is an active and well-tolerated regimen in patients with relapsed or refractory multiple myeloma","volume":"123","author":"Ludwig","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0350","doi-asserted-by":"crossref","first-page":"v1","DOI":"10.1093\/annonc\/mdu438.29","article-title":"Carfilzomib (K) vs low-dose corticosteroids and optional cyclophosphamide (Cy) in patients (pts) with relapsed and refractory multiple myeloma (RRMM): results from a phase 3 study (FOCUS)","volume":"25","author":"Ludwig","year":"2014","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0355","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1111\/j.1365-2141.2008.07409.x","article-title":"High response rate to bortezomib with or without dexamethasone in patients with relapsed or refractory multiple myeloma: results of a global phase 3b expanded access program","volume":"144","author":"Mikhael","year":"2009","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0360","doi-asserted-by":"crossref","first-page":"311","DOI":"10.3324\/haematol.2009.012674","article-title":"Peripheral neuropathy and new treatments for multiple myeloma: background and practical recommendations","volume":"95","author":"Mohty","year":"2010","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0365","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/leu.2011.310","article-title":"Treatment strategies in relapsed and refractory multiple myeloma: a focus on drug sequencing and \u2018retreatment' approaches in the era of novel agents","volume":"26","author":"Mohty","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0370","doi-asserted-by":"crossref","first-page":"113","DOI":"10.1002\/hon.2149","article-title":"Therapy-related peripheral neuropathy in multiple myeloma patients","volume":"33","author":"Morawska","year":"2014","journal-title":"Hematol. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0375","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1016\/S1470-2045(11)70081-X","article-title":"Subcutaneous versus intravenous administration of bortezomib in patients with relapsed multiple myeloma: a randomised, phase 3, non-inferiority study","volume":"12","author":"Moreau","year":"2011","journal-title":"Lancet Oncol."},{"issue":"Suppl. 6","key":"10.1016\/j.critrevonc.2017.02.007_bib0380","doi-asserted-by":"crossref","first-page":"vi133","DOI":"10.1093\/annonc\/mdt297","article-title":"Multiple myeloma: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"24","author":"Moreau","year":"2013","journal-title":"Ann. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0385","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","article-title":"Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma","volume":"374","author":"Moreau","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0390","series-title":"Levact","author":"Napp Pharmaceuticals Ltd","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0395","doi-asserted-by":"crossref","first-page":"336","DOI":"10.1002\/cncr.25584","article-title":"Phase 2 trial of the histone deacetylase inhibitor romidepsin for the treatment of refractory multiple myeloma","volume":"117","author":"Niesvizky","year":"2011","journal-title":"Cancer"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0400","series-title":"Farydak (Panobinostat) Summary of Product Characteristics","author":"Novartis","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0405","first-page":"133","article-title":"Low-dose thalidomide with pegylated liposomal doxorubicin and high-dose dexamethasone for relapsed\/refractory multiple myeloma: a prospective, multicenter, phase II study","volume":"91","author":"Offidani","year":"2006","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0410","doi-asserted-by":"crossref","first-page":"e162","DOI":"10.1038\/bcj.2013.58","article-title":"Efficacy and tolerability of bendamustine, bortezomib and dexamethasone in patients with relapsed-refractory multiple myeloma: a phase II study","volume":"3","author":"Offidani","year":"2013","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0415","series-title":"Onyx Pharmaceuticals Kyprolis\u2122 Highlights of Prescribing Information","author":"Onyx Pharmaceuticals","year":"2015"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0420","doi-asserted-by":"crossref","first-page":"3892","DOI":"10.1200\/JCO.2006.10.5460","article-title":"Randomized phase III study of pegylated liposomal doxorubicin plus bortezomib compared with bortezomib alone in relapsed or refractory multiple myeloma: combination therapy improves time to progression","volume":"25","author":"Orlowski","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0425","first-page":"399","article-title":"Low-dose thalidomide plus dexamethasone is an effective salvage therapy for advanced myeloma","volume":"86","author":"Palumbo","year":"2001","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0430","doi-asserted-by":"crossref","first-page":"414","DOI":"10.1038\/sj.leu.2405062","article-title":"Prevention of thalidomide- and lenalidomide-associated thrombosis in myeloma","volume":"22","author":"Palumbo","year":"2008","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0435","doi-asserted-by":"crossref","first-page":"1716","DOI":"10.1038\/leu.2009.122","article-title":"International Myeloma Working Group guidelines for the management of multiple myeloma patients ineligible for standard high-dose chemotherapy with autologous stem cell transplantation","volume":"23","author":"Palumbo","year":"2009","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0440","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","article-title":"Daratumumab, bortezomib, and dexamethasone for multiple myeloma","volume":"375","author":"Palumbo","year":"2016","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0445","doi-asserted-by":"crossref","first-page":"205","DOI":"10.1007\/s00432-005-0074-4","volume":"132","author":"Ponisch","year":"2006","journal-title":"J. Cancer Res. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0450","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1111\/ijlh.12097","article-title":"United Kingdom Myeloma Forum (UKMF) position statement on the use of bendamustine in myeloma","volume":"36","author":"Pratt","year":"2013","journal-title":"Int. J. Lab. Hematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0455","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1182\/blood.V124.21.301.301","article-title":"Phase 1 study update of the novel pan-pim kinase inhibitor LGH447 in patients with relapsed\/refractory multiple myeloma","volume":"124","author":"Raab","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0460","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8012","article-title":"Einsele H, et al. MOR202 alone and in combination with pomalidomide or lenalidomide in relapsed or refractory multiple myeloma: data from clinically relevant cohorts from a phase I\/IIa study","volume":"34","author":"Raab","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0465","doi-asserted-by":"crossref","first-page":"e451","DOI":"10.1038\/bcj.2016.53","article-title":"New investigational drugs with single-agent activity in multiple myeloma","volume":"6","author":"Rajan","year":"2016","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0470","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1016\/S1470-2045(09)70284-0","article-title":"Lenalidomide plus high-dose dexamethasone versus lenalidomide plus low-dose dexamethasone as initial therapy for newly diagnosed multiple myeloma: an open-label randomised controlled trial","volume":"11","author":"Rajkumar","year":"2010","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0475","doi-asserted-by":"crossref","first-page":"2609","DOI":"10.1056\/NEJMoa030288","article-title":"A phase 2 study of bortezomib in relapsed, refractory myeloma","volume":"348","author":"Richardson","year":"2003","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0480","doi-asserted-by":"crossref","first-page":"2487","DOI":"10.1056\/NEJMoa043445","article-title":"Bortezomib or high-dose dexamethasone for relapsed multiple myeloma","volume":"352","author":"Richardson","year":"2005","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0485","doi-asserted-by":"crossref","first-page":"3458","DOI":"10.1182\/blood-2006-04-015909","article-title":"A randomized phase 2 study of lenalidomide therapy for patients with relapsed or relapsed and refractory multiple myeloma","volume":"108","author":"Richardson","year":"2006","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0490","doi-asserted-by":"crossref","first-page":"3557","DOI":"10.1182\/blood-2006-08-036947","article-title":"Extended follow-up of a phase 3 trial in relapsed multiple myeloma: final time-to-event results of the APEX trial","volume":"110","author":"Richardson","year":"2007","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0495","doi-asserted-by":"crossref","first-page":"595","DOI":"10.1038\/leu.2011.346","article-title":"Management of treatment-emergent peripheral neuropathy in multiple myeloma","volume":"26","author":"Richardson","year":"2012","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0500","doi-asserted-by":"crossref","first-page":"1038","DOI":"10.1182\/blood-2014-01-548826","article-title":"Phase 1 study of twice-weekly ixazomib, an oral proteasome inhibitor, in relapsed\/refractory multiple myeloma patients","volume":"124","author":"Richardson","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0505","doi-asserted-by":"crossref","DOI":"10.1200\/jco.2015.33.15_suppl.tps8610","article-title":"Investigators. M-S. MM-007: a phase 3 trial comparing the efficacy and safety of pomalidomide (POM), bortezomib (BORT), and low-dose dexamethasone (LoDEX [PVD]) versus BORT and LoDEX (VD) in subjects with relapsed or refractory multiple myeloma (RRMM)","volume":"33","author":"Richardson","year":"2015","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0510","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8005","article-title":"Updated data from a phase II dose finding trial of single agent isatuximab (SAR650984, anti-CD38 mAb) in relapsed\/refractory multiple myeloma (RRMM)","volume":"34","author":"Richter","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0515","doi-asserted-by":"crossref","first-page":"e56","DOI":"10.3324\/haematol.2014.110890","article-title":"Phase II study of bendamustine, bortezomib and dexamethasone as second-line treatment for elderly patients with multiple myeloma: the Intergroupe Francophone du Myelome 2009-01 trial","volume":"100","author":"Rodon","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0520","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","article-title":"Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial","volume":"14","author":"San Miguel","year":"2013","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0525","doi-asserted-by":"crossref","first-page":"1195","DOI":"10.1016\/S1470-2045(14)70440-1","article-title":"Panobinostat plus bortezomib and dexamethasone versus placebo plus bortezomib and dexamethasone in patients with relapsed or relapsed and refractory multiple myeloma: a multicentre, randomised, double-blind phase 3 trial","volume":"15","author":"San-Miguel","year":"2014","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0530","doi-asserted-by":"crossref","first-page":"e506","DOI":"10.1016\/S2352-3026(16)30147-8","article-title":"Overall survival of patients with relapsed multiple myeloma treated with panobinostat or placebo plus bortezomib and dexamethasone (the PANORAMA 1 trial): a randomised, placebo-controlled, phase 3 trial","volume":"3","author":"San-Miguel","year":"2016","journal-title":"Lancet Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0535","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1182\/blood.V126.23.378.378","article-title":"Oprozomib, pomalidomide, and dexamethasone (OPomd) in patients (Pts) with relapsed and\/or refractory multiple myeloma (RRMM): initial results of a phase 1b study (NCT01999335)","volume":"126","author":"Shah","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0540","doi-asserted-by":"crossref","first-page":"2817","DOI":"10.1182\/blood-2012-05-425934","article-title":"A phase 2 study of single-agent carfilzomib (PX-171-003-A1) in patients with relapsed and refractory multiple myeloma","volume":"120","author":"Siegel","year":"2012","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0545","doi-asserted-by":"crossref","first-page":"1753","DOI":"10.3324\/haematol.2013.089334","article-title":"Integrated safety profile of single-agent carfilzomib: experience from 526 patients enrolled in 4 phase II clinical studies","volume":"98","author":"Siegel","year":"2013","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0550","doi-asserted-by":"crossref","first-page":"e182","DOI":"10.1038\/bcj.2014.1","article-title":"Vorinostat in combination with lenalidomide and dexamethasone in patients with relapsed or refractory multiple myeloma","volume":"4","author":"Siegel","year":"2014","journal-title":"Blood Cancer J."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0555","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1056\/NEJM199911183412102","article-title":"Antitumor activity of thalidomide in refractory multiple myeloma","volume":"341","author":"Singhal","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0560","doi-asserted-by":"crossref","first-page":"410","DOI":"10.1111\/j.1365-2141.2005.05867.x","article-title":"Guidelines on the diagnosis and management of multiple myeloma 2005","volume":"132","author":"Smith","year":"2006","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0565","doi-asserted-by":"crossref","first-page":"e63","DOI":"10.3324\/haematol.2014.112557","article-title":"Health-related quality of life from the MM-003 trial of pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone in relapsed and\/or refractory multiple myeloma","volume":"100","author":"Song","year":"2015","journal-title":"Haematologica"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0570","doi-asserted-by":"crossref","first-page":"2946","DOI":"10.1200\/JCO.2011.39.6820","article-title":"Bortezomib induction and maintenance treatment in patients with newly diagnosed multiple myeloma: results of the randomized phase III HOVON-65\/GMMG-HD4 trial","volume":"30","author":"Sonneveld","year":"2012","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0575","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1038\/leu.2013.185","article-title":"Review of health-related quality of life data in multiple myeloma patients treated with novel agents","volume":"27","author":"Sonneveld","year":"2013","journal-title":"Leukemia"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0580","doi-asserted-by":"crossref","first-page":"2955","DOI":"10.1182\/blood-2016-01-631200","article-title":"Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group","volume":"127","author":"Sonneveld","year":"2016","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0585","doi-asserted-by":"crossref","first-page":"4220","DOI":"10.1182\/blood.V126.23.4220.4220","article-title":"Phase 1, multicenter, open-label, combination study (NPI-0052-107; NCT02103335) of pomalidomide (POM), marizomib (MRZ, NPI-0052), and low-dose dexamethasone (LD-DEX) in patients with relapsed and refractory multiple myeloma","volume":"126","author":"Spencer","year":"2015","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0590","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1111\/j.1600-0609.2009.01257.x","article-title":"Lenalidomide in combination with dexamethasone at first relapse in comparison with its use as later salvage therapy in relapsed or refractory multiple myeloma","volume":"82","author":"Stadtmauer","year":"2009","journal-title":"Eur. J. Haematol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0595","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","article-title":"Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma","volume":"372","author":"Stewart","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0600","series-title":"Ninlaro (Ixazomib) Summary of Product Characteristics","author":"Takeda","year":"2016"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0605","doi-asserted-by":"crossref","first-page":"111","DOI":"10.1016\/S1548-5315(11)70861-0","article-title":"Thalidomide in multiple myeloma","volume":"2","author":"Tucker","year":"2005","journal-title":"Commun. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0610","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1182\/blood.V124.21.34.34","article-title":"Clinical profile of single-agent oprozomib in patients (Pts) with multiple myeloma (MM): updated results from a multicenter, open-label, dose escalation phase 1b\/2 study","volume":"124","author":"Vij","year":"2014","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0615","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2016.34.15_suppl.8009","article-title":"Mazuir F, et al. A phase Ib dose escalation trial of isatuximab (SAR650984, anti-CD38 mAb) plus lenalidomide and dexamethasone (Len\/Dex) in relapsed\/refractory multiple myeloma (RRMM): interim results from two new dose cohorts","volume":"34","author":"Vij","year":"2016","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0620","doi-asserted-by":"crossref","first-page":"4445","DOI":"10.1182\/blood-2008-02-141614","article-title":"Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure","volume":"112","author":"Wang","year":"2008","journal-title":"Blood"},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0625","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1056\/NEJMoa070596","article-title":"Lenalidomide plus dexamethasone for relapsed multiple myeloma in North America","volume":"357","author":"Weber","year":"2007","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0630","doi-asserted-by":"crossref","first-page":"1569","DOI":"10.1016\/S1470-2045(16)30375-8","article-title":"Ricolinostat plus lenalidomide, and dexamethasone in relapsed or refractory multiple myeloma: a multicentre phase 1b trial","volume":"17","author":"Yee","year":"2016","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.critrevonc.2017.02.007_bib0635","doi-asserted-by":"crossref","first-page":"1993","DOI":"10.1007\/s00277-014-2149-2","article-title":"Lenalidomide in relapsed and refractory multiple myeloma disease: feasibility and benefits of long-term treatment","volume":"93","author":"Zago","year":"2014","journal-title":"Ann. Hematol."}],"container-title":["Critical Reviews in Oncology\/Hematology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817300604?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1040842817300604?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T13:21:27Z","timestamp":1719062487000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1040842817300604"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2017,4]]},"references-count":127,"alternative-id":["S1040842817300604"],"URL":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.007","relation":{},"ISSN":["1040-8428"],"issn-type":[{"value":"1040-8428","type":"print"}],"subject":[],"published":{"date-parts":[[2017,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"How have evolutions in strategies for the treatment of relapsed\/refractory multiple myeloma translated into improved outcomes for patients?","name":"articletitle","label":"Article Title"},{"value":"Critical Reviews in Oncology\/Hematology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.critrevonc.2017.02.007","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Amgen Inc. Published by Elsevier Ireland Ltd.","name":"copyright","label":"Copyright"}]}}